NCT05316116View on ClinicalTrials.gov

Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

October 18, 2024

Study Completion Date

October 18, 2024

Conditions
Large Granular Lymphocyte Leukemia
Interventions
DRUG

Siltuximab

Siltuximab will be given on day 1 of each cycle. The dose will be 11 mg/kg given over 1 hour by intravenous infusion. Each cycle is three weeks (+-3 days).

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

EUSA Pharma, Inc.
All Listed Sponsors
collaborator

EUSA Pharma, Inc.

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER